Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ymthe.2020.12.016 http://scihub22266oqcxt.onion/10.1016/j.ymthe.2020.12.016 33333292!7834738!33333292     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Ther 2021 ; 29 (2): 873-885 Nephropedia Template TP {{tp|p=33333292|t=2021. Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 |pdf=|usr=}}{{33333292}} gab.com Text Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 JO: Mol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33333292 #FOAvip Antiviral drug development for coronavirus disease 2019 (COVID-19) is occurring at an unprecedented pace, yet there are still limited therapeutic options for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2, thus generating better antiviral efficacy. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro. Sixteen synergistic and eight antagonistic combinations were identified; among 16 synergistic cases, combinations of the US Food and Drug Administration (FDA)-approved drug nitazoxanide with remdesivir, amodiaquine, or umifenovir were most notable, all exhibiting significant synergy against SARS-CoV-2 in a cell model. However, the combination of remdesivir and lysosomotropic drugs, such as hydroxychloroquine, demonstrated strong antagonism. Overall, these results highlight the utility of drug repurposing and preclinical testing of drug combinations for discovering potential therapies to treat COVID-19. Twit Text FOAVip Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 ????Mol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33333292 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33333292 #FOAvip English Wikipedia <ref>{{Cite pmid|33333292}}</ref> Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 #MMPMID33333292 Bobrowski T; Chen L; Eastman RT; Itkin Z; Shinn P; Chen CZ; Guo H; Zheng W; Michael S; Simeonov A; Hall MD; Zakharov AV; Muratov EN Mol Ther 2021[Feb]; 29 (2): 873-885 PMID33333292show ga Antiviral drug development for coronavirus disease 2019 (COVID-19) is occurring at an unprecedented pace, yet there are still limited therapeutic options for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2, thus generating better antiviral efficacy. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro. Sixteen synergistic and eight antagonistic combinations were identified; among 16 synergistic cases, combinations of the US Food and Drug Administration (FDA)-approved drug nitazoxanide with remdesivir, amodiaquine, or umifenovir were most notable, all exhibiting significant synergy against SARS-CoV-2 in a cell model. However, the combination of remdesivir and lysosomotropic drugs, such as hydroxychloroquine, demonstrated strong antagonism. Overall, these results highlight the utility of drug repurposing and preclinical testing of drug combinations for discovering potential therapies to treat COVID-19. |*COVID-19 Drug Treatment[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Drug Combinations[MESH] |Drug Synergism[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH]Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing